Please login to the form below

Not currently logged in
Email:
Password:

ABT-530

This page shows the latest ABT-530 news and features for those working in and with pharma, biotech and healthcare.

AbbVie hepatitis C combo shows high cure rates

AbbVie hepatitis C combo shows high cure rates

The new phase II data on NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 - which recently started pivotal trials - showed that 97-98% of patients with genotype ... AbbVie is hoping to be able to show that ABT-493/ABT-530 can achieve high

Latest news

  • AbbVie takes 'one-size-fits-all' HCV regimen into phase III AbbVie takes 'one-size-fits-all' HCV regimen into phase III

    The co-formulated drug - which combines NS3/4A protease inhibitor ABT-493 with NS5A inhibitor ABT-530 - will be tested in six phase III trials involving patients with HCV genotypes

  • Hepatitis C therapies: dawn of a new age Hepatitis C therapies: dawn of a new age

    AbbVie is developing a DAA-based, IFN-free regimen centred on the protease inhibitor ABT 450. ... AbbVie is co-formulating its next-generation compounds ABT 530 and ABT 493, its ritonavir-free protease inhibitor, and Gilead has GS 5816 poised for phase 3

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics